Stimulation du nerf vague dans le traitement de la dépression

Senova, Suhan; Rabu, Corentin; Beaumont, Sami; Michel, Valériane; Palfi, Stéphane; Mallet, Luc; Domenech, Philippe

doi:10.1016/j.lpm.2019.10.019

Cited by 12 publications

(5 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is gratifying that in the past five years of research, people’s attention to physical therapy has gradually increased. Researchers have verified the effectiveness and safety of the above treatment techniques from different perspectives and have explored ways to achieve better efficacy[ 21 , 26 , 27 , 46 ]. Most of the time, satisfactory results can be obtained.…”

Section: Discussionmentioning

confidence: 99%

“…Although vagus nerve stimulation (VNS) was initially widely used to treat epilepsy (and not depression), because it can effectively improve the mood of patients with epilepsy, VNS has been extended to include mental disorders such as depression. In 2005, the Food and Drug Administration in the United States officially approved VNS for the treatment of depression[ 46 ]. It has been rapidly developed and has achieved positive outcomes.…”

Section: Vagus Nerve Stimulationmentioning

confidence: 99%

See 1 more Smart Citation

Physiotherapy for patients with depression: Recent research progress

Liu,

Sun,

Meng

et al. 2024

World J Psychiatry

View full text Add to dashboard Cite

Depression, a common mental illness, seriously affects the health of individuals and has deleterious effects on society. The prevention and treatment of depression has drawn the attention of many researchers and has become an important social issue. The treatment strategies for depression include drugs, psychotherapy, and physiotherapy. Drug therapy is ineffective in some patients and psychotherapy has treatment limitations. As a reliable adjuvant therapy, physiotherapy compensates for the shortcomings of drug and psychotherapy and effectively reduces the disease recurrence rate. Physiotherapy is more scientific and rigorous, its methods are diverse, and to a certain extent, provides more choices for the treatment of depression. Physiotherapy can relieve symptoms in many ways, such as by improving the levels of neurobiochemical molecules, inhibiting the inflammatory response, regulating the neuroendocrine system, and increasing neuroplasticity. Physiotherapy has biological effects similar to those of antidepressants and may produce a superimposed impact when combined with other treatments. This article summarizes the findings on the use of physiotherapy to treat patients with depression over the past five years. It also discusses several methods of physiotherapy for treating depression from the aspects of clinical effect, mechanism of action, and disadvantages, thereby serving as a reference for the in-depth development of physiotherapy research.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Vagus Nerve Stimulationmentioning

confidence: 99%

Physiotherapy for patients with depression: Recent research progress

Liu,

Sun,

Meng

et al. 2024

World J Psychiatry

View full text Add to dashboard Cite

show abstract

“…Corollary to this, vagus nerve stimulation (VNS) as a way to counteract disrupted vagus nerve signaling may hold promise as a novel therapeutic approach in AUD. VNS is already approved as an adjunctive therapy for patients with epilepsy and depression that are resistant to pharmacological treatment, however the mechanisms involved in these effects remains elusive (Senova et al, 2019;Toffa et al, 2020). Preclinical studies with VNS reveal that activating afferent vagal sensory neurons via electrode stimulation alters central neuronal signaling which may help rectify circuits regulating heroin and cocaine intake and seeking (Liu et al, 2011;Childs et al, 2017).…”

Section: Clinical Relevance Of Dorsal Vagal Complex Neurotransmitter ...mentioning

confidence: 99%

Involvement of the Dorsal Vagal Complex in Alcohol-Related Behaviors

Keller

Hajnal

Browning

et al. 2022

Front. Behav. Neurosci.

View full text Add to dashboard Cite

The neurobiological mechanisms that regulate the development and maintenance of alcohol use disorder (AUD) are complex and involve a wide variety of within and between systems neuroadaptations. While classic reward, preoccupation, and withdrawal neurocircuits have been heavily studied in terms of AUD, viable treatment targets from this established literature have not proven clinically effective as of yet. Therefore, examination of additional neurocircuitries not classically studied in the context of AUD may provide novel therapeutic targets. Recent studies demonstrate that various neuropeptides systems are important modulators of alcohol reward, seeking, and intake behaviors. This includes neurocircuitry within the dorsal vagal complex (DVC), which is involved in the control of the autonomic nervous system, control of intake of natural rewards like food, and acts as a relay of interoceptive sensory information via interactions of numerous gut-brain peptides and neurotransmitter systems with DVC projections to central and peripheral targets. DVC neuron subtypes produce a variety of neuropeptides and transmitters and project to target brain regions critical for reward such as the mesolimbic dopamine system as well as other limbic areas important for the negative reinforcing and aversive properties of alcohol withdrawal such as the extended amygdala. This suggests the DVC may play a role in the modulation of various aspects of AUD. This review summarizes the current literature on neurotransmitters and neuropeptides systems in the DVC (e.g., norepinephrine, glucagon-like peptide 1, neurotensin, cholecystokinin, thyrotropin-releasing hormone), and their potential relevance to alcohol-related behaviors in humans and rodent models for AUD research. A better understanding of the role of the DVC in modulating alcohol related behaviors may lead to the elucidation of novel therapeutic targets for drug development in AUD.

show abstract

“…Since the optimal clinical effects of tDCS are delayed, future clinical trials should use longer evaluation periods and aim to identify responsive patients using algorithms[ 137 ].…”

Section: Somatic Treatmentsmentioning

confidence: 99%

Major depressive disorder: Validated treatments and future challenges

Karrouri¹,

Hammani²,

Benjelloun³

et al. 2021

WJCC

View full text Add to dashboard Cite

Depression is a prevalent psychiatric disorder that often leads to poor quality of life and impaired functioning. Treatment during the acute phase of a major depressive episode aims to help the patient reach a remission state and eventually return to their baseline level of functioning. Pharmacotherapy, especially selective serotonin reuptake inhibitors antidepressants, remains the most frequent option for treating depression during the acute phase, while other promising pharmacological options are still competing for the attention of practitioners. Depression-focused psychotherapy is the second most common option for helping patients overcome the acute phase, maintain remission, and prevent relapses. Electroconvulsive therapy is the most effective somatic therapy for depression in some specific situations; meanwhile, other methods have limits, and their specific indications are still being studied. Combining medications, psychotherapy, and somatic therapies remains the most effective way to manage resistant forms of depression.

show abstract

Stimulation du nerf vague dans le traitement de la dépression

Cited by 12 publications

References 64 publications

Physiotherapy for patients with depression: Recent research progress

Physiotherapy for patients with depression: Recent research progress

Involvement of the Dorsal Vagal Complex in Alcohol-Related Behaviors

Major depressive disorder: Validated treatments and future challenges

Contact Info

Product

Resources

About